Abstract:Objective— Revascularization is an essential process to compensate for cardiac underperfusion and, therefore, preserves cardiac function in the face of chronic ischemic injury. Recent evidence suggested a vital role of aldehyde dehydrogenase 2 (ALDH2) in cardiac protection after ischemia. This study was designed to determine whether ALDH2 regulates chronic ischemia−induced angiogenesis and to explore the underlying mechanism involved. Moreover, the clinical impact of the ALDH2 mutant allele on the development of coronary collateral circulation (CCC) was evaluated. Approach and Results— Mice limb ischemia was performed. Compared with wild-type, ALDH2 deletion significantly reduced perfusion recovery, small artery and capillary density, and increased muscle atrophy in this ischemic model. In vitro, ALDH2-knockdown reduced proliferation, migration and hypoxia triggered endothelial tube formation of endothelial cells, the effects of which were restored by ALDH2 transfection. Further examination revealed that ALDH2 regulated angiogenesis possibly through hypoxia-inducible factor-1α/vascular endothelial growth factor pathways. To further discern the role of ALDH2 deficiency in the function of bone marrow stem/progenitor cells, cross bone marrow transplantation was performed between wild-type and ALDH2-knockout mice. However, there was no significant improvement for wild-type bone marrow transplantation into knockout mice. ALDH2 genotyping was screened in 139 patients with chronic total occlusion recruited to Zhongshan Hospital (2011.10–2014.4). Patients with poor CCC (Rentrop 0–1; n=51) exhibited a higher frequency of the AA genotype than those with enriched CCC (Rentrop 2–3; n=88; 11.76% versus 1.14%; P =0 0.01). However, the AA group displayed less enriched CCC frequency in Logistic regression model when compared with the GG group (odds ratio=0.08; 95% confidence interval, 0.009–0.701; P =0 0.026). Furthermore, serum vascular endothelial growth factor level tended to be lower in patients with ALDH2 mutation. Conclusions— This study demonstrated that ALDH2 possesses an intrinsic capacity to regulate angiogenesis via hypoxia-inducible factor-1α and vascular endothelial growth factor. Patients with ALDH2-deficient genotype displayed a higher risk of developing poor CCC. Therapeutic individualization based on ALDH2 allele distribution may thus improve the therapeutic benefit, especially in the East Asian decedents.

Mitochondrial Aldehyde Dehydrogenase 2 Regulates Revascularization in Chronic Ischemia

Mitochondrial Aldehyde Dehydrogenase 2 Regulates Revascularization in Chronic Ischemia: Potential Impact on the Development of Coronary Collateral Circulation.

Characterization of the Molecular Mechanisms Underlying Increased Ischemic Damage in the Aldehyde Dehydrogenase 2 Genetic Polymorphism Using a Human Induced Pluripotent Stem Cell Model System.

Alda-1 treatment promotes the therapeutic effect of mitochondrial transplantation for myocardial ischemia-reperfusion injury

Aldehyde Dehydrogenase-2 Roles in Ischemic Cardiovascular Disease.

Mitochondrial Aldehyde Dehydrogenase-2 Deficiency Compromises Therapeutic Effect of ALDH Bright Cell on Peripheral Ischemia.

Aldehyde dehydrogenase 2 and arrhythmogenesis

Aldehyde Dehydrogenase 2 Deficiency Blunts Compensatory Cardiac Hypertrophy Through Modulating Akt Phosphorylation Early after Transverse Aorta Constriction in Mice.

Loss of M6a Demethylase ALKBH5 Promotes Post‐ischemic Angiogenesis Via Post‐transcriptional Stabilization of WNT5A

Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype

Aldehyde Dehydrogenase 2 Preserves Mitochondrial Function in the Ischemic Heart: A Redox-dependent Mechanism for AMPK Activation by Thioredoxin-1

Aldehyde Dehydrogenase 2 Preserves Mitochondrial Morphology and Attenuates Hypoxia/reoxygenation-Induced Cardiomyocyte Injury.

Abstract 19679: Mitochondrial Aldehyde Dehydrogenase 2 (ALDH2) Ameliorates Angiotensin II-Induced Cardiac Remodeling and Myocardial Dysfunction through Inhibition of Mitochondrial Oxidative Stress and Induction of Autophagy

Mitochondrial Aldehyde Dehydrogenase in Myocardial Ischemia-Reperfusion Injury: from Bench to Bedside.

Mitochondrial Aldehyde Dehydrogenase 2*2 Allele Carriers Possess Better Cardioprotection Results After Cardioplegic Arrest During Open-Heart Surgery

Mitochondrial Aldehyde Dehydrogenase 2 Plays Protective Roles in Heart Failure After Myocardial Infarction via Suppression of the Cytosolic JNK/p53 Pathway in Mice

Activation of Aldehyde Dehydrogenase-2 Reduces Ischemic Damage to the Heart

Aldehyde Dehydrogenase 2 (ALDH2) Rescues Myocardial Ischaemia/reperfusion Injury: Role of Autophagy Paradox and Toxic Aldehyde

Activation of aldehyde dehydrogenase 2 slows down the progression of atherosclerosis via attenuation of ER stress and apoptosis in smooth muscle cells

Abstract 20516: Aldehyde Dehydrogenase 2 Deficiency Promotes Vascular Smooth Muscle Cell Migration, Proliferation and Accelerates Neointima Formation

Effect Of Mitochondrial Aldehyde Dehydrogenase-2 Genotype On Cardioprotection In Patients With Congenital Heart Disease